SCHEMBL6538760

SCHEMBL6538760

CC(C)CNC(=O)COc1ccccc1C(=O)OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.52
PARP1 P09874 1/20 0.51
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
TDP1 Q9NUW8 2/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HPGD P15428 1/20 0.46
GBA1 P04062 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
SGMS2 Q8NHU3 1/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539278 0.85 HTT (0.57) HTTPARP1ALDH1A1SMN1; SMN2TDP1
SCHEMBL6538497 0.85 ALDH1A1 (0.56) HTTPARP1ALDH1A1SMN1; SMN2NPSR1
SCHEMBL6539788 0.83 PARP1 (0.55) HTTPARP1ALDH1A1SMN1; SMN2MEN1
SCHEMBL6538759 0.82 SMN1; SMN2 (0.59) HTTALDH1A1SMN1; SMN2TDP1MEN1
SCHEMBL6539750 0.79 HTT (0.65) HTTALDH1A1SMN1; SMN2TDP1MEN1
SCHEMBL6538569 0.79 HTT (0.55) HTTALDH1A1SMN1; SMN2TDP1MEN1
SCHEMBL4415350 0.77 HTT (0.75) HTTPARP1ALDH1A1SMN1; SMN2TDP1
SCHEMBL8380993 0.77 HTT (0.59) HTTALDH1A1SMN1; SMN2TDP1MEN1
SCHEMBL27898281 0.76 L3MBTL1 (0.66) HTTALDH1A1SMN1; SMN2TDP1MEN1
SCHEMBL6539802 0.76 HTT (0.58) HTTALDH1A1SMN1; SMN2TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB HTT 3050/4885PARP1 4137/4885ALDH1A1 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.